Abstract Introduction
Introduction
The increased risk of severe influenza in preschool children 1 has prompted the use of seasonal influenza vaccines in this age group. Routine influenza vaccination of healthy young children using trivalent influenza vaccine (TIV) is recommended in many countries including the United States and Canada. 2 and 3 Large case series have shown this to be well tolerated and rarely associated with serious adverse events including seizures. 4 hypothesise that excessive pyrogenic cytokine production contributed to the adverse events.
We explored this hypothesis using an in vitro stimulation model in which peripheral blood mononuclear cells (PBMCs) from young children (12-36 months of age) were challenged with different TIV preparations and cytokine responses assessed.
Materials and Methods

Clinical data
Princess Margaret Hospital is the only tertiary paediatric hospital in the state of WA (population 2.26 million) with more than 65,000 emergency paediatric presentations per year.
Admission or discharge diagnoses are available through the WA Emergency Department Information System. Children presenting from the 8th March 2010 to 25th April 2010 with possible immunization-related adverse events were identified retrospectively using ICD-10 diagnostic codes: R56.0 (febrile convulsion), T88.8 (other vaccination complication), R50.9
(febrile illness of unknown origin), B34.9 (viral illness), G40.3 (generalized idiopathic epilepsy and epileptic syndromes), T80.5 (anaphylactic shock due to immunization) and T80.6 (vaccination complicated by allergic reaction).
9
A vaccine-related febrile adverse reaction was defined as any child presenting within 72 h of TIV with a documented fever (>37.5 °C as recorded by health-care providers or parents)
where an alternative source of fever was not identified clinically and/or microbiologically.
Febrile convulsions were identified using published definitions. 10 All adverse events were reviewed by one author (CCB) to ensure consistency of data collection. 
Immunological experiments
Clinical samples were routinely stored by our pathology service at 4-8 °C for 7 days following collection. Plasma samples were collected into tubes containing lithium heparin No baseline values for cytokine levels in plasma from healthy children have been reported for this age group. Cytokine levels from clinical samples were therefore compared with baseline 'normal' values established in plasma from healthy preschool children participating in a study investigating ear disease.
Potential mechanisms for the reaction were explored using an in vitro model
PBMCs ( Adverse events were most frequently observed in children ≤2 years of age ( 30.8%, p < 0.03).
Plasma samples from six subjects with vaccine-related febrile convulsions were available upon suspension of the program (supplemental table A). All plasma samples were collected within 27 h of immunization; four samples were taken within 60 min of febrile convulsion.
None of the children had had previous febrile convulsions. One child had a seizure disorder and five of six subjects had no predisposing medical conditions. Only one child received other vaccines at the time of TIV. When measured, IP-10 (CXCL10) and macrophage inflammatory protein (MIP) 1α were significantly higher in plasma from subjects compared with normal values (p < 0.0001 and p = 0.02, respectively). A trend towards higher plasma levels of the pyrogenic cytokines IFNα, IL-1β and IL-6 and regulatory cytokine IL-10 in subjects was observed (Fig. 1) . No differences were observed in TNFα, IL-8 and IFNγ levels (data not shown).
In the in vitro vaccine PBMC stimulation model, IFN-α, IL-1β, IL-6, IL-10, IP-10 and MIP-1α levels were all significantly higher in cultures stimulated for 6 h with Fluvax ® compared to those stimulated with Influvac ® or Vaxigrip ® (Fig. 2) , with the levels further increased after 24 h (data not shown). A partial response to Influvac ® was observed for IL-6 and MIP-1α in some cultures (p = 0.051 and 0.0025 compared to Vaxigrip), yet levels were half, to one-tenth that seen with Fluvax ® in the same cultures at 6 h. TNF-α production was detected after Fluvax ® stimulation in only in 14 of 22 cultures with relatively low levels that did not increase significantly from 6 to 24 h (mean: 44 pg/ml and 56 pg/ml respectively). IFN-γ was low/undetectable after 6 or 24 h vaccine stimulation but was significantly induced by SEB (data not shown).
Discussion
Safety of TIV has been demonstrated following immunization of preschool children in numerous populations. 4 Increased pyrogenic cytokines were present in plasma of a small subset of children sustaining febrile adverse events compared with plasma levels in healthy age-matched controls. These findings compelled us to explore whether rapid, cytokine driven, febrile reactions to This research demonstrates the clear differences between preparations of TIV. It is possible that these are related to differences in the manufacturing process. This investigation highlights the importance of ongoing global safety monitoring for all TIV preparations in all age groups. This needs to be performed annually given the changing formulation of influenza vaccines. Increased awareness amongst manufacturers, immunization providers, family practitioners and emergency physicians of potential adverse events following TIV is required to ensure earlier detection and prevention of significant febrile adverse events in the future.
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